Cargando…

Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradáčová, Pavla, Slavík, Luděk, Skoumalová, Adéla, Úlehlová, Jana, Kriegová, Eva, Manukyan, Gayane, Friedecký, David, Piskláková, Barbora, Ullrychová, Jana, Procházková, Jana, Hluší, Antonín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409152/
https://www.ncbi.nlm.nih.gov/pubmed/36012233
http://dx.doi.org/10.3390/ijms23168973
_version_ 1784774780650520576
author Bradáčová, Pavla
Slavík, Luděk
Skoumalová, Adéla
Úlehlová, Jana
Kriegová, Eva
Manukyan, Gayane
Friedecký, David
Piskláková, Barbora
Ullrychová, Jana
Procházková, Jana
Hluší, Antonín
author_facet Bradáčová, Pavla
Slavík, Luděk
Skoumalová, Adéla
Úlehlová, Jana
Kriegová, Eva
Manukyan, Gayane
Friedecký, David
Piskláková, Barbora
Ullrychová, Jana
Procházková, Jana
Hluší, Antonín
author_sort Bradáčová, Pavla
collection PubMed
description Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test.
format Online
Article
Text
id pubmed-9409152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94091522022-08-26 Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome Bradáčová, Pavla Slavík, Luděk Skoumalová, Adéla Úlehlová, Jana Kriegová, Eva Manukyan, Gayane Friedecký, David Piskláková, Barbora Ullrychová, Jana Procházková, Jana Hluší, Antonín Int J Mol Sci Article Antiphospholipid syndrome (APS) is a hypercoagulable state accompanied by the presence of heterogeneous antiphospholipid antibodies (aPL), which nonspecifically affect hemostasis by the presence of lupus anticoagulans (LA), anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein-I (anti-β2GPI), but also non-criteria antibodies such as antibodies against β2-glycoprotein-I domain I (anti-DI), anti-phosphatidylserine/prothrombin (anti-PS/PT), anti-annexin V, and many others. The main target of the antibodies is the activated protein C (APC) system, the elimination of which can manifest itself as a thrombotic complication. The aim of this study was to determine the thrombogenicity of antibodies using a modified protein C-activated thrombin generation assay (TGA) on a group of 175 samples suspected of APS. TGA was measured with/without APC and the ratio of both measurements was evaluated (as for APC resistance), where a cut-off was calculated ≤4.5 (90th percentile) using 21 patients with heterozygous factor V Leiden mutation (FV Leiden heterozygous). Our study demonstrates the well-known fact that multiple positivity of different aPLs is a more severe risk for thrombosis than single positivity. Of the single antibody positivity, LA antibodies are the most serious (p value < 0.01), followed by aCL and their subgroup anti-DI (p value < 0.05). Non-criteria antibodies anti-annexin V and anti-PT/PS has a similar frequency occurrence of thrombogenicity as LA antibodies but without statistical significance or anti-β2GPI1 positivity. The modified TGA test can help us identify patients in all groups who are also at risk for recurrent thrombotic and pregnancy complications; thus, long-term prophylactic treatment is appropriate. For this reason, it is proving increasingly beneficial to include the determination antibodies in combination with modified TGA test. MDPI 2022-08-11 /pmc/articles/PMC9409152/ /pubmed/36012233 http://dx.doi.org/10.3390/ijms23168973 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bradáčová, Pavla
Slavík, Luděk
Skoumalová, Adéla
Úlehlová, Jana
Kriegová, Eva
Manukyan, Gayane
Friedecký, David
Piskláková, Barbora
Ullrychová, Jana
Procházková, Jana
Hluší, Antonín
Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
title Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
title_full Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
title_fullStr Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
title_full_unstemmed Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
title_short Determination of Thrombogenicity Levels of Various Antiphospholipid Antibodies by a Modified Thrombin Generation Assay in Patients with Suspected Antiphospholipid Syndrome
title_sort determination of thrombogenicity levels of various antiphospholipid antibodies by a modified thrombin generation assay in patients with suspected antiphospholipid syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409152/
https://www.ncbi.nlm.nih.gov/pubmed/36012233
http://dx.doi.org/10.3390/ijms23168973
work_keys_str_mv AT bradacovapavla determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT slavikludek determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT skoumalovaadela determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT ulehlovajana determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT kriegovaeva determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT manukyangayane determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT friedeckydavid determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT pisklakovabarbora determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT ullrychovajana determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT prochazkovajana determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome
AT hlusiantonin determinationofthrombogenicitylevelsofvariousantiphospholipidantibodiesbyamodifiedthrombingenerationassayinpatientswithsuspectedantiphospholipidsyndrome